Analyzing PolyPid (NASDAQ:PYPD) and Dyne Therapeutics (NASDAQ:DYN)

PolyPid (NASDAQ:PYPD) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares PolyPid and Dyne Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$29.02 million	($2.98)	-1.34
Dyne Therapeutics	N/A	N/A	-$317.42 million	($3.66)	-6.07

Dyne Therapeutics is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

PolyPid has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.

Profitability

This table compares PolyPid and Dyne Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-313.65%	-128.32%
Dyne Therapeutics	N/A	-66.17%	-56.35%

Analyst Recommendations

This is a summary of recent ratings and price targets for PolyPid and Dyne Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1	0	6	1	2.88
Dyne Therapeutics	1	3	12	4	2.95

PolyPid presently has a consensus price target of $12.40, suggesting a potential upside of 211.56%. Dyne Therapeutics has a consensus price target of $37.44, suggesting a potential upside of 68.64%. Given PolyPid’s higher probable upside, equities analysts plainly believe PolyPid is more favorable than Dyne Therapeutics.

Insider & Institutional Ownership

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 24.7% of PolyPid shares are owned by company insiders. Comparatively, 20.8% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.